2023 

1. Park, J.-C. et al. MutSα and MutSβ as size-dependent cellular determinants for prime editing in human embryonic stem cells. Molecular Therapy-Nucleic Acids, (2023).

2. Park, J.-C., Kim, K.-T., Jang, H.-K. & Cha, H.-J. Transition Substitution of Desired Bases in Human Pluripotent Stem Cells with Base Editors: A Step-by-Step Guide. International Journal of Stem Cells 16, 234, (2023).

3. Kwon, E.-J. & Cha, H.-J. Deep Learning Approach Based on Transcriptome Profile for Data Driven Drug Discovery. Molecules and Cells, 46, 65, (2023).

4. Koo, K.-M. et al. Label-free and non-destructive identification of naïve and primed embryonic stem cells based on differences in cellular metabolism. Biomaterials 293, 121939, (2023).

5. Kim, Y.-J. et al. TPX2 prompts mitotic survival via the induction of BCL2L1 through YAP1 protein stabilization in human embryonic stem cells. Experimental & Molecular Medicine, 1-11, (2023).

6. Ho-Chang Jeong, Y.-H. G., Joong-Gon Shin, Yun-Jeong Kim, Min-Guk Cho, Dasom Gwon, Hyun Sub Cheong, Haeseung Lee , Jae-Ho Lee, Chang-Young Jang, Hyoung Doo Shin, Hyuk-Jin Cha. TPX2 Amplification-Driven Aberrant Mitosis in Culture Adapted Human Embryonic Stem Cells with gain of 20q11.21. Stem Cell Review and Report, (2023).

7. Kwon EJ et al, In Silico Discovery of 5′-Modified 7-Deoxy-7-ethynyl-4′-thioadenosine as a HASPIN Inhibitor and Its Synergistic Anticancer Effect with the PLK1 Inhibitor. ACS Central Science 9 (6), 1140

8. Park JC et al, Gene editing with ‘pencil’rather than ‘scissors’ in human pluripotent stem cells. Stem Cell Research & Therapy 14 (1), 1-12

 

2022

1. Park, J.-C. et al. Multiple isogenic GNE-myopathy modeling with mutation specific phenotypes from human pluripotent stem cells by base editors. Biomaterials 282, 121419, (2022).

2. Park, J.-C. et al. High expression of uracil DNA glycosylase determines C to T substitution in human pluripotent stem cells. Molecular Therapy-Nucleic Acids 27, 175-183, (2022).

3. Kim, S. Y. et al. The Korean undiagnosed diseases program phase I: expansion of the nationwide network and the development of long-term infrastructure. Orphanet Journal of Rare Diseases 17, 1-11, (2022).

4. Kim, S.-M. et al. Dichotomous role of Shp2 for naïve and primed pluripotency maintenance in embryonic stem cells. Stem Cell Research & Therapy 13, 1-14, (2022).

5. Kim, K.-T. et al. Live isolation of naïve ESCs via distinct glucose metabolism and stored glycogen. Metabolic Engineering 72, 97-106, (2022).

6. Choi, S.-K. et al. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations. Cellular Oncology 45, 913-930, (2022).

 

2021

1. MiasiroáCiaramicoli, L., SeokáKim, H. & HyunáYu, Y. Target identification of mouse stem cell probe CDy1 as ALDH2 and Abcb1b through live-cell affinity-matrix and ABC CRISPRa library. RSC Chemical Biology 2, 1590-1593, (2021).

2. Kong, H. J. et al. Crosstalk between YAP and TGFβ regulates SERPINE1 expression in mesenchymal lung cancer cells. International Journal of Oncology 58, 111-121, (2021).

3. Hwang, S.-Y. et al. L1 retrotransposons exploit RNA m6A modification as an evolutionary driving force. Nature communications 12, 880, (2021).

4. Choi, J. Y. et al. TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells. Molecular Oncology 15, 679-696, (2021).

 

2020

1. Kwon, O.-S. et al. Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer. Oncogene 39, 4567-4580, (2020).

2. Kwon, O.-S. et al. ERK dephosphorylation through MKP1 deacetylation by SIRT1 attenuates RAS-driven tumorigenesis. Cancers 12, 909, (2020).

3. Kwon, O.-S. et al. Systematic identification of a nuclear receptor-enriched predictive signature for erastin-induced ferroptosis. Redox Biology 37, 101719, (2020).

4. Kim, K.-T. et al. Safe scarless cassette-free selection of genome-edited human pluripotent stem cells using temporary drug resistance. Biomaterials 262, 120295, (2020).

5. Kim, D.-H. et al. Nuclear factor erythroid-derived 2-like 2-induced reductive stress favors self-renewal of breast cancer stem-like cells via the FoxO3a-Bmi-1 Axis. Antioxidants & Redox Signaling 32, 1313-1329, (2020).

6. Go, Y.-H. et al. Luteolin Induces Selective Cell Death of Human Pluripotent Stem Cells. Biomedicines 8, 453, (2020).

 

2019

 

1          Kwon, T., Kwon, O.-S., Cha, H.-J. & Sung, B. J. Stochastic and heterogeneous cancer cell migration: experiment and theory. Scientific reports 9, 1-13, (2019).

2          Kwon, O.-S., Kim, W., Cha, H.-J. & Lee, H. In silico drug repositioning: from large-scale transcriptome data to therapeutics. Archives of pharmacal research 42, 879-889, (2019).

3          Kaushik, N. et al. Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation. Cell Communication and Signaling 17, 1-13, (2019).

4          Go, Y.-H. et al. Structure-activity relationship analysis of YM155 for inducing selective cell death of human pluripotent stem cells. Frontiers in Chemistry 7, 298, (2019).

5          Bae, H., Go, Y.-H., Kwon, T., Sung, B. J. & Cha, H.-J. A theoretical model for the cell cycle and drug induced cell cycle arrest of FUCCI systems with cell-to-cell variation during mitosis. Pharmaceutical Research 36, 1-13, (2019).

 

2018

1.  Yoon, D., Cha, H.-J., Lee, J.-S. & Chun, W. Enhancement of wound healing efficiency mediated by artificial dermis functionalized with EGF or NRG1. Biomedical Materials 13, 045007, (2018).

2. Seong, K. M. et al. Proactive strategy for long-term biological research aimed at low-dose radiation risk in Korea. International Journal of Radiation Biology 94, 685-693, (2018).

3. Kwon, O.-S. et al. In silico Drug Repositioning of bortezomib to reverse metastatic effect of GALNT14 in lung cancer. bioRxiv, 394163, (2018).

4. Kwon, O.-S. et al. Designing tyrosinase siRNAs by multiple prediction algorithms and evaluation of their anti-melanogenic effects. Biomolecules & Therapeutics 26, 282, (2018).

5.  Kim, J. H. et al. Optimizing tissue-clearing conditions based on analysis of the critical factors affecting tissue-clearing procedures. Scientific reports 8, 12815, (2018).

6. Kim, D. J. et al. Covalent Functionalization of FeCo/Graphitic Shell Nanocrystals via 1, 3‐Dipolar Cycloaddition. ChemNanoMat 4, 132-139, (2018).

7. Im, J. H. et al. Inhibition of BET selectively eliminates undifferentiated pluripotent stem cells. Science Bulletin 63, 477-487, (2018).

8. Hong, S.-K. et al. Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer. Molecular cancer 17, 1-7, (2018).

9. Go, Y.-H. et al. Screening of cytotoxic or cytostatic flavonoids with quantitative Fluorescent Ubiquitination-based Cell Cycle Indicator-based cell cycle assay. Royal Society open science 5, 181303, (2018).

10. Cui, Y.-H. et al. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation. Oncogene 37, 5794-5809, (2018).

11. Cho, S.-J. et al. A fluorescent chemical probe CDy9 selectively stains and enables the isolation of live naive mouse embryonic stem cells. Biomaterials 180, 12-23, (2018).

12. Cho, S.-J. et al. Selective elimination of culture-adapted human embryonic stem cells with BH3 mimetics. Stem cell reports 11, 1244-1256, (2018).